FCFS

155.61

+0.75%↑

RPT.US

2.54

+2.83%↑

FCFS

155.61

+0.75%↑

RPT.US

2.54

+2.83%↑

FCFS

155.61

+0.75%↑

RPT.US

2.54

+2.83%↑

FCFS

155.61

+0.75%↑

RPT.US

2.54

+2.83%↑

FCFS

155.61

+0.75%↑

RPT.US

2.54

+2.83%↑

Search

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

186.75 -1.68

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

182.45

Max

190

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-23M

93M

Pardavimai

400K

745M

P/E

Sektoriaus vid.

69.078

31.165

Pelnas, tenkantis vienai akcijai

0.94

Pelno marža

12.43

Darbuotojai

10,134

EBITDA

-55M

201M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.27% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

174M

20B

Ankstesnė atidarymo kaina

188.43

Ankstesnė uždarymo kaina

186.75

Naujienos nuotaikos

By Acuity

36%

64%

139 / 528 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-17 18:59; UTC

Pagrindinės rinkos jėgos

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

2025-11-17 23:40; UTC

Rinkos pokalbiai

Gold Consolidates Amid Mixed Signals -- Market Talk

2025-11-17 23:34; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-11-17 22:58; UTC

Rinkos pokalbiai

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

2025-11-17 22:46; UTC

Rinkos pokalbiai

Risk Assets Set to Have a Strong 2026 -- Market Talk

2025-11-17 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

2025-11-17 22:02; UTC

Uždarbis

Trip.com Group 3Q Rev $2.6B >TCOM

2025-11-17 22:02; UTC

Uždarbis

Trip.com Group 3Q Adj EPS $3.87 >TCOM

2025-11-17 22:02; UTC

Uždarbis

Trip.com Group 3Q EPS $4.02 >TCOM

2025-11-17 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-11-17 21:40; UTC

Uždarbis

James Hardie Industries 2Q Adj EPS 26c >JHX

2025-11-17 21:40; UTC

Uždarbis

James Hardie Industries 2Q Loss/Shr 10c >JHX

2025-11-17 21:39; UTC

Uždarbis

James Hardie Industries 2Q Sales $1.29B >JHX

2025-11-17 21:38; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025-11-17 21:38; UTC

Uždarbis

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

2025-11-17 21:10; UTC

Uždarbis

XP Inc. 3Q EPS BRL2.47 >XP

2025-11-17 21:10; UTC

Uždarbis

XP Inc. 3Q Rev BRL4.67B >XP

2025-11-17 20:20; UTC

Rinkos pokalbiai

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

2025-11-17 20:12; UTC

Rinkos pokalbiai

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

2025-11-17 20:12; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-11-17 20:09; UTC

Rinkos pokalbiai

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

2025-11-17 19:29; UTC

Rinkos pokalbiai

Gold Slide Continues to Start Week -- Market Talk

2025-11-17 19:16; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025-11-17 18:20; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

2025-11-17 16:45; UTC

Įsigijimai, susijungimai, perėmimai

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

2025-11-17 16:16; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025-11-17 16:15; UTC

Uždarbis

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

2025-11-17 15:40; UTC

Įsigijimai, susijungimai, perėmimai

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

2025-11-17 15:22; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

2025-11-17 15:19; UTC

Rinkos pokalbiai

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

20.27% į viršų

12 mėnesių prognozė

Vidutinis 228.57 EUR  20.27%

Aukščiausias 246 EUR

Žemiausias 210 EUR

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

5

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

139 / 528 reitingas Finansų sektorius

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat